Toxicity of infliximab in the course of treatment of Crohn’s disease

Bibliography

• MANOGUE K, VAN DEVENTER S, CERAMI A: Tumour necrosis factor alpha or cachectin. Cytokine Handbook. London: Academic Press (1991):241-256.
   Google Scholar
• BEUTLER B: An evolutionary approach to the TNF alpha receptor/ligand family. Ann. NY Acad. Sci. (1994) 730:118-133.
   PubMed Web of Science ®Google Scholar
• TRACEY K, CERAMI A: Tumor necrosis factor: a pleiotropic cytokine and therapeutic target. Ann. Rev. Med. (1994) 45:491-503.
   PubMed Web of Science ®Google Scholar
• VAN DEVENTER S: Tumour necrosis factor and Crohn’s Disease. Gut (1997) 40:443-448.
   PubMed Web of Science ®Google Scholar
• MYATT N, GOGHILL G, MORRISON K, JONES D, CREE I: Detection of tumour necrosis factor alpha in sarcoidosis and tuberculosis granulomas using in situ hybridization. J. Clin. Pathol. (1994) 47:423-426.
   PubMed Web of Science ®Google Scholar
• TSUJI M, DIMOV V, YOSHIDA T: In vivo expression of monokine and inducible nitric oxide synthase in experimentally induced pulmonary inflammation. Evidence for sequential production of interleukin-1, inducible nitric oxide synthase and tumor necrosis factor. Am. J. Pathol. (1995) 147:1001-1015.
   PubMed Web of Science ®Google Scholar
• CHENSU S, WARMINGTON K, RUTH J, LINCOLN P, KUNKEL S: Cytokine function during mycobacterial and schistosomal antigen-induced pulmonary granuloma formation. Local and regional participation of IFN-gamma, IL-10 and TNF. J. Immunol. (1995) 154:5969-5976.
   PubMed Web of Science ®Google Scholar
• BREESE E, MICHIE C, NICHOLLS S et al.: Tumor necrosis factor alpha-producing cells in the intestinal mucous of children with inflammatory bowel disease. Gastroenterology (1994) 106:1455-1566.
   PubMed Web of Science ®Google Scholar
• REINECKER H, STEFFEN M, WITTHOEFT T et al.: Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn’s disease. Clin. Exp. Immun. (1993) 94:174-181.
   PubMed Web of Science ®Google Scholar
• POWRIE F, LESCH M, MAUZE S, MENON S, CADDLE L, COFFMAN R: Inhibition of Th1 responses prevents inflammatory bowel disease in scid mice reconstituted with CD45Rbhi CD4+ T cells. Immunity (1994) 1:553-562.
   PubMed Web of Science ®Google Scholar
• NEURATH M, FUSS I, KELSALL B, PRESKY D, WAEGELL W, STROBER W: Experimental granulomatous colitis in mice is abrogated by induction of TGF-(beta)-mediated oral tolerance. J. Exp. Med. (1996) 183:2605-2616.
   PubMed Web of Science ®Google Scholar
• DAVIDSON N, LEACH M, FORT M et al.: T helper cell 1-type CD4+ T cells, but not B cells, mediate colitis in interleukin 10-deficient mice. J. Exp. Med. (1996) 184:241-251.
   PubMed Web of Science ®Google Scholar
• MOSMANN T, COFFMAN R: TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Ann. Rev. Immunol. (1989) 7:145-173.
   PubMed Web of Science ®Google Scholar
• PIRMEZ, C, YAMAMURA M, UYEMURA K, PAES-OLIVEIRA M, CONCEICAO-SILVA F, MODLIN R: Cytokine patters in the pathogenesis of human leishmaniasis. J. Clin. Invest. (1993) 91:1390-1395.
   PubMed Web of Science ®Google Scholar
• KNIGHT D, TRINH H, LE J et al.: Construction and initial characterization of a mouse-human anti-TNF-antibody. Mol. Immunol. (1993) 30:1443-1453.
   PubMed Web of Science ®Google Scholar
• VAN DULLEMEN H, VAN DEVENTER S, HOMMES D et al.: Treatment of Crohn’s disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology (1995) 109:129-135.
   PubMed Web of Science ®Google Scholar
• MCCABE R, WOODY J, VAN DEVENTER S et al.: A multicenter trial of cA2 anti-TNF chimeric monoclonal antibody in patients with active Crohn’s disease. Gastroenterology (1996) 110:(Suppl.):A962 Abstract.
   Web of Science ®Google Scholar
• TARGAN S, HANAUER S, VAN DEVENTER S et al.: A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor (alpha) for Crohn’s disease. N. Engl. J. Med. (1997) 337:1029-1035.
   PubMed Web of Science ®Google Scholar
• D’HAENS G, VAN DEVENTER S, VAN HOGEZAND R et al.: Endoscopic and histological healing with infliximab antibodies in Crohn’s disease: a European multicenter trial. Gastroenterology (1999) 116:1029-1034.
   PubMed Web of Science ®Google Scholar
• PRESENT D, RUTGEERTS P, TARGAN S et al.: Infliximab for the treatment of fistulas in patients with Crohn’s Disease. N. Engl. J. Med. (1999) 340:1398-1405.
   PubMed Web of Science ®Google Scholar
• HANAUER S, FEAGAN B, LICHTENSTEIN G et al.: Maintenance infliximab for Crohn’s disease: the ACCENT I randomized trial. Lancet (2002) 359:1541-1549.
   PubMed Web of Science ®Google Scholar
• COLOMBEL J, LOFTUS E, TREMAINE W et al.: The safety profile of infliximab for Crohn’s disease in clinical practice: the Mayo Clinic experience in 500 patients. Gastroenterology (2004) 126:19-31.
   PubMed Web of Science ®Google Scholar
• SANDS B, BLANK M, PATEL K, VAN DEVENTER S: ACCENT II Study.Long-term treatment of rectovaginal fistulas in Crohn’s disease: response to infliximab in the ACCENT II Study. Clin. Gastroenterol. Hepatol. (2004) 10:912-1920.
   Google Scholar
• PINCUS T, STEIN C: Why randomized controlled clinical trials do not depict accurately long-term outcomes in rheumatoid arthritis: some explanations and suggestions for future studies. Clin. Exp. Rheumatol. (1997) 15(Suppl. 17):S27-S38.
   PubMed Web of Science ®Google Scholar
• GOLDMAN S: Limitations and strengths of spontaneous reports data. Clin. Ther. (1998) 20(Suppl. C):C40-C44.
   Google Scholar
• HYRICH K, SILMAN A, WATSON K, SYMMONS D: Anti-tumour necrosis factor α therapy in rheumatoid arthritis: an update on safety. Ann. Rheum. Dis. (2004) 63:1538-1543.
   PubMed Web of Science ®Google Scholar
• LICHTENSTEIN G, COHEN R, FEAGAN B et al.: Safety of infliximab and other Crohn’s disease therapies-updated TREAT Registry data with over 10,000 patient-years of follow-up. Gastroenterology (2005) 128(Suppl. 2):A580.
   PubMed Web of Science ®Google Scholar
• ROOK G, TAVERN J, LEVETON C, STEELE J: The role of gamma-interferon, vitamin D3 metabolites and tumour necrosis factor in the pathogenesis of tuberculosis. Immunology (1987) 62:229-234.
   PubMed Web of Science ®Google Scholar
• TRAMONTANA J, UTAIPAT U, MOLLOY A et al.: Thalidomide treatment reduces tumor necrosis factor alpha production and enhances weight gain in patients with pulmonary tuberculosis. Mol. Med. (1995) 1:384-397.
   PubMed Web of Science ®Google Scholar
• SENALDI G, YIN S: Corynebacterium parvum and Mycobacterium bovis bacillus Calmette-Guerin-induced granuloma formation is inhibited in TNF receptor I (TNF-RI) knockout mice and by treatment with soluble TNF-RI. J. Immunol. (1996) 157:5022-5026.
   PubMed Web of Science ®Google Scholar
• KINDLER V, SAPPINO A, BRAU G, PIGUET P, VASSALLI P: The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell (1989) 56:731-740.
   PubMed Web of Science ®Google Scholar
• BEKKER L, FREEMAN S, MURRAY P, RYFFEL B, KAPLAN G: TNF-alpha controls intracellular mycobacterial growth by both inducible nitric oxide synthase-dependent and inducible nitric oxide synthase-independent pathways. J. Immunol. (2001) 166:6728-6734.
   PubMed Web of Science ®Google Scholar
• MOHAN V, SCANGA C, YU K et al.: Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: possible role for limiting pathology. Infect. Immun. (2001) 69:1847-1855.
   PubMed Web of Science ®Google Scholar
• KEANE J, GERSHON S, WISE R et al.: Tuberculosis associated with infliximab, a tumor necrosis factor (alpha)-neutralizing agent. N. Engl. J. Med. (2001) 345:1098-1104.
   PubMed Web of Science ®Google Scholar
• COSTAMANGA P, FURST K, TULLY K et al.: Tuberculosis associated with blocking agents against tumor necrosis factor-alpha-California, 2002-2003. MMWR (2004) 53:683-686.
   PubMedGoogle Scholar
• FROM THE CENTERS FOR DISEASE CONTROL AND PREVENTION. Tuberculosis associated with blocking agents against tumor necrosis factor-alpha. JAMA (2004) 292:1677.
   Google Scholar
• VAVRICKA S, WETTSTEIN T, SPEICH R, GASPERT A, BACHLI E: Pulmonary granulomas after tumour necrosis factor alpha antagonist therapy. Thorax (2003) 58:278-279.
   PubMed Web of Science ®Google Scholar
• CAMUSSI G, ALBANO E, TETTA C, BUSSOLINO F: The molecular action of tumor necrosis factor-alpha. Eur. J. Biochem. (1991) 202:3-14.
   PubMedGoogle Scholar
• NO AUTHORS LISTED: Remicade® (infliximab) prescribing information.
   Google Scholar
• YOUNG J, MCGWIRE B: To the editor: Infliximab and Reactivation of Cerebral Toxoplasmosis. N. Engl. J. Med. (2005) 353:1530-1531.
   PubMed Web of Science ®Google Scholar
• SING S, RAU N, COHEN L, HARRIS H: Cutaneous nocardiosis complicating management of Crohn’s disease with infliximab and prednisone. CMAJ (2004) 171:1063-1064.
   PubMed Web of Science ®Google Scholar
• HARNEY S, O’SHEA F, FITZGERALD O: Peptostreptococcal pericarditis complicating anti-tumor necrosis factor α treatment in rheumatoid arthritis. Ann. Rheum. Dis. (2002) 61:653-654
   Google Scholar
• AMERICAN THORACIC SOCIETY, CENTERS FOR DISEASE CONTROL AND PREVENTION: Targeted tuberculin testing and treamtent of latent tuberculsosi infection. Am. J. Repir. Crit. Care Med. (2000) 161:S221-S247.
   PubMed Web of Science ®Google Scholar
• O’CONNOR M, BUCHMAN A, MARSHALL G: Anaphylaxis-like reaction to infliximab in a patient with Crohn’s disease. Dig. Dis. Sci. (2002) 47:1323-1325.
   PubMed Web of Science ®Google Scholar
• LANKARANI K: Mortality associated with infliximab. J. Clin. Gastronterol. (2001) 33:255-256.
   PubMed Web of Science ®Google Scholar
• DIAMANTI A, MASSIMO C, PAPADATOU B, FERRETTI F, GAMBARARA M: Severe anaphylactic reaction to infliximab in pediatric patients with Crohn’s disease. J. Pediatr. (2002) 140:636-637.
   PubMedGoogle Scholar
• HYAMS J, MARKOWITZ, J, WYLLIE R: Severe anaphylactic reaction to infliximab in pediatric patients with Crohn’s disease –reply. J. Pediatr. (2002) 140:637.
   PubMedGoogle Scholar
• ZHANG Z, CORREA H, BEGUE R: Tuberculosis and treatment with infliximab. N. Engl. J. Med. (2002) 346(8):623-626.
   PubMedGoogle Scholar
• DWEIK M, DUARTE A: ARDS due to coccidiomycosis infection in a non-endemic area associated with infliximab. Chest (2004) 126(Suppl.):976S.
   Web of Science ®Google Scholar
• WARRIS A, BJORNEKLETT A, GAUSTAD P: Invasive pulmonary aspergillosis associated with infliximab therapy. N. Engl. J. Med. (2001) 344:1099-1100.
   PubMed Web of Science ®Google Scholar
• PANAGI S, PALKA W, KORELITZ B, TASKIN M, LESSNAU K: Diffuse alveolar hemorrhage after infliximab treatment of Crohn’s disease. Inflamm. Bowel Dis. (2004) 10:274-277.
   PubMed Web of Science ®Google Scholar
• STALLMACH A, BIESE T, SCHMIDT C, MEUER S, ZEUZEM S: Severe anaphylactic reaction to infliximab: successful treatment with adalimumab – report of a case. Eur. J. Gastroen. Hepat. (2004) 16:627-630.
   PubMed Web of Science ®Google Scholar
• GREENSTEIN A, SACHAR D, SMITH H et al.: Patterns of neoplasia in Crohn’s disease and ulcerative colitis. Cancer (1980) 46:403-407.
   PubMed Web of Science ®Google Scholar
• WOOLRICH A, DASILVA M, KORELITZ B: Surveillance in the routine management of ulcerative colitis: predictive value of low-grade dysplasia. Gastroenterology (1992) 103:431-438.
   PubMed Web of Science ®Google Scholar
• KANDIEL A, FRASER A, KORELITZ B et al.: Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut (2005) 54:1121-1115.
   PubMed Web of Science ®Google Scholar
• LJUNG T, KARLÉN P, SCHMIDT D et al.: Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County. Gut (2004) 53:849-853.
   PubMed Web of Science ®Google Scholar
• GEBOREK P, BLADSTROM A, TURESSON C et al.: Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann. Rheum. Dis. (2005) 64:699-703.
   PubMed Web of Science ®Google Scholar
• BROWN S, GREENE M, GERSHON S et al.: Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum. (2002) 46:3151-3158.
   PubMed Web of Science ®Google Scholar
• COHEN C, HORSTER S, SANDER C, BOGNER J: Kaposi’s sarcoma associated with tumor necrosis factor [alpha] neutralizing therapy. Ann. Rheum. Dis. (2003) 62:684.
   PubMed Web of Science ®Google Scholar
• BROBERGER O, PERLMANN P: Autoantibodies in human ulcerative colitis. J. Exp. Med. (1959) 110:657.
   PubMed Web of Science ®Google Scholar
• ZAULI D, CRESPI C, DALL’AMORE P, BIANCHI F, PISI E: Antibodies to the cytoskeleton components and other autoantibodies in inflammatory bowel disease. Digestion (1985) 32:140-144.
   PubMed Web of Science ®Google Scholar
• DALEKOS G, MANOUSSAKIS M, GOUSSIA A, TSIANOS E, MOUTSOPOULOS H: Soluble interleukin-2 receptors anti-neutrophil cytoplasmic antibodies and other autoantibodies in patients with ulcerative colitis. Gut (1993) 34:658-664.
   PubMed Web of Science ®Google Scholar
• REUMAUX D, MEZIERE C, COLOMBEL J, CUTHILLEUL P, MUELLER S: Distinct production of autoantibodies to nuclear components in ulcerative colitis and Crohn’s disease. Clin Immunol. Immunop. (1995) 77:349-357.
   PubMedGoogle Scholar
• FOLAWACZNY C, NOEHL N, ENDRES S, HELWEIN W, LOESCHKE K, FRICKE H: Antinuclear autoantibodies in patients with inflammatory bowel disease. High prevalence in first-degree relatives. Dig. Dis. Sci. (1997) 42:1593-1597.
   PubMed Web of Science ®Google Scholar
• GARCIA-PLANELLA E, DOMENECH E, ESTEVE-COMAS M et al.: Development of antinuclear antibodies and its clinical impact in patients with Crohn’s disease treated with chimeric monoclonal anti-TNF [alpha] antibodies (infliximab). Eur. J. Gastoenterol. Hepatol. (2003) 15:352-354.
   Google Scholar
• WEBER R: Adverse reactions to biological modifiers. Curr. Opin. Allergy Clin. Immunol. (2004) 4:277-283.
   PubMedGoogle Scholar
• VERMEIRE S, NOMAN M, VAN ASSCHE G et al.: Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn’s disease: a prospective cohort study. Gastroenterology (2003) 125:32-39.
   PubMed Web of Science ®Google Scholar
• CHARLES P, SMEENK R, DE JONG J, FELDMANN M, MAINI R: Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum. (2000) 43:2383-2390.
   PubMed Web of Science ®Google Scholar
• BOBBIO-PALLAVICINI F, ALPINI C, CAPORALI R, AVALLE S, BUGATTI S, MONTECUCCO C: Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment. Arthritis Res. Ther. (2004) 6:R264-R272.
   PubMed Web of Science ®Google Scholar
• DE RYCKE L, KRUITHOF E, VAN DAMME N et al.: Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondyloarthropathy. Arthritis Rheum. (2003) 48:1015-1023.
   PubMed Web of Science ®Google Scholar
• BAERT F, NOMAN M, VERMEIRE S VAN ASSCHE G, D’HAENS G, CARBONEZ A: Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. N. Engl. J. Med. (2003) 348:601-608.
   PubMed Web of Science ®Google Scholar
• RUTGEERS P, D’HAENS G, TARGAN S, VISILIAUSKAS E, HANAUER S, PRESENT D et al.: Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn’s disease. Gastroenterology (1999) 117:761-769.
   PubMed Web of Science ®Google Scholar
• BAERT F, RUTGEERTS P: Anti-TNF strategies in Crohn’s disease: mechanisms, clinical effects, indications. Ing. J. Colorectal Dis. (1999) 14:47-51.
   PubMed Web of Science ®Google Scholar
• FARRELL R, ALSAHLI M, JEEN Y, FALCHUK K, PEPPERCORN M, MICHETTI P: Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn’s disease: a randomized controlled trial. Gastroenterology (2003) 124:917-924.
   PubMed Web of Science ®Google Scholar
• ROTT S, MROWIETZ U: Recent developments in the use of biologics in psoriasis and autoimmune disorders. The role of autoantibodies. Br. Med. J. (2005) 330:716-720.
   PubMed Web of Science ®Google Scholar
• PUTTINI P, ARDIZZONE S, MANZIONNA G et al.: Infliximab-induced lupus in Crohn’s disease: a case report. Dig. Liver Dis. (2003) 35:814-817.
   PubMedGoogle Scholar
• KLAPMAN J, ENE-STROESCU D, BECKER M, HANAUER S: A lupus-like syndrome associated with infliximab therapy. Inflamm. Bowel Dis. (2003) 9:176-178.
   PubMed Web of Science ®Google Scholar
• CHEIFITZ A, SMEDLEY M, MARTIN S, REITER M, LEONE G, MAYER L: The incidence and management of infusion reactions to infliximab: a large center experience. Am. J. Gastroenterol. (2003) 98:1315-1324.
   PubMed Web of Science ®Google Scholar
• CRANDALL W, MACKNER L: Infusion reactions to infliximab in children and adolescents: frequency, outcome and a predictive model. Aliment. Pharmacol. Ther. (2003) 17:75-84.
   PubMed Web of Science ®Google Scholar
• JACOBSTEIN D, MARKOWITZ J, KIRSHNER B, FERRY G, COHEN S, GOLD B et al.: Premedication and infusion reactions with infliximab: results from a pediatric inflammatory bowel disease consortium. Inflamm. Bowel Dis. (2005) 11:442-446.
   PubMed Web of Science ®Google Scholar
• LEVINE B, KALMAN J, MAYER L et al.: Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N. Engl. J. Med. (1990) 323:236-241.
   PubMed Web of Science ®Google Scholar
• BRADHAM W, BOZKURT B, GUNASINGHE H et al.: Tumor necrosis factor-alpha and myocardial remodeling in progression of heart failure: a current perspective. Cardiovasc. Res. (2002) 53:822-830.
   PubMed Web of Science ®Google Scholar
• AIKAWA R, NITTA-KOMATSUBARA Y, KUDOH S et al.: Reactive oxygen species induce cardiomyocyte apoptosis partly through TNF-alpha. Cytokine (2002) 18:179-83.
   PubMed Web of Science ®Google Scholar
• BOZKURT B, TORRE-AMIONE G, WARREN M et al.: Results of targeted anti-tumor necrosis factor therapy with etanercept (Enbrel) in patients with advanced heart failure. Circulation (2001) 103:1044-1047.
   PubMed Web of Science ®Google Scholar
• CHUNG E, PACKER M, HUNG K, FASANMADE A, WILLERSON J: Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-α, in patients with moderate-to-severe heart failure. Circulation (2003) 107:3133-3140.
   PubMed Web of Science ®Google Scholar
• KWON H, COTE T, CUFFE M, KRAMER J, BRAUN M: Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann. Intern. Med. (2003) 138:807-811.
   PubMed Web of Science ®Google Scholar
• MOHAN N, EDWARDS E, CUPPS T et al.: Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum. (2001) 44:2862-2869.
   PubMed Web of Science ®Google Scholar
• ROBINSON W, GENOVESE M, MORELAND L: Demyelinating and neurological events reported in association with tumor necrosis factor alpha antagonism: by what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis? Arthritis Rheum. (2001) 44:1977-1983.
   PubMed Web of Science ®Google Scholar
• PEDRAM E, KONSTANTINOS A: Association of anti-tumor necrosis factor therapy with the development of multiple sclerosis. J. Clin. Gastroenterol. (2005) 39:303-306.
   PubMed Web of Science ®Google Scholar
• VAN OOSTEN B, BARKHOF F, TRUYEN L et al.: Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology (1996) 47:1531-1534.
   PubMed Web of Science ®Google Scholar
• RICHEZ C, BLANCO P, LAGUENY A, SCHAEVERBEKE T, DEHAIS J: Neuropathy resembling CIDP in patients receiving tumor necrosis factor-[alpha] blockers. Neurology (2005) 64:1468-1470.
   PubMed Web of Science ®Google Scholar
• SINGER, O, OTTO, B, STEINMETZ, H, ZIEMANN, U: Acute neuropathy with multiple conduction blocks after TNF [alpha] monoclonal antibody therapy. Neurology (2004) 63:1754.
   PubMed Web of Science ®Google Scholar
• MEJICO L: Infliximab-associated retrobulbar optic neuritis. Arch. Ophthalmol. (2004) 122:793-794.
   PubMed Web of Science ®Google Scholar
• STRONG B, ERNY B, HERZENBERG H, RAZZECA K: Retrobulbar Optic Neuritis Associated with Infliximab in a Patient with Crohn’s Disease. Ann. Intern. Med. (2004) 140:677-678.
   PubMed Web of Science ®Google Scholar
• FOROOZAN R, BUONO L, SERGOTT R, SAVINO P: Retrobulbar optic neuritis associated with infliximab. Arch. Ophthalmol. (2002) 120:985-987.
   PubMed Web of Science ®Google Scholar
• MENGHINI V, AMINDRA S: Infliximab-associated reversible cholestatic liver disease. Mayo Clin. Proc. (2001) 76:84-86.
   PubMed Web of Science ®Google Scholar
• BHATIA J, KORELITZ B, PANAGOPOULOS G et al.: Infliximab versus hydrocortisone for Crohn’s disease patients requiring hospitalization. Am. J. Gastroenterol. (2005) 100(Suppl. 9):S297.
   Google Scholar